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columns. The eicosanoids were eluted with 2 ml isopropanol. The eluent was dried under vacuum and the samples were reconstituted in 100 μl of 50:50 EtOH:dH 2 O for LC/MS/MS analysis.
The reconstituted eicosanoids were analyzed via HPLC ESI-MS/MS. A 30 minute reversed-phase LC method utilizing a Kinetex C18 column (100 x 2.1mm, 2.6 µm) was used to separate the eicosanoids at a flow rate of 200 µl/min at 50°C. The column was equilibrated with 100% Solvent A (acetonitrile:water:formic acid (40:60:0.02, v/v/v)) for five minutes and then 10 µl of sample was injected. 100% Solvent A was used for the first minute of elution. Solvent B (acetonitrile:isopropanol (50:50, v/v)) was increased in a linear gradient to 25% Solvent B to 3 minutes, to 45% until 11 minutes, to 60% until 13 minutes, to 75% until 18 minutes, and to 100% until 20 minutes. 100% Solvent B was held until 25 minutes, then was decreased to 0% in a linear gradient until 26 minutes, and then held until 30 minutes. The eicosanoids were then analyzed using a tandem quadrupole mass spectrometer (ABI 4000 Q-Trap®, Applied Biosystems) via multiple-reaction monitoring in negative-ion mode. Eicosanoids were monitored using precursor → product multiple reaction monitoring (MRM) pairs, which can be found in Supplemental Table 2 . The mass spectrometer parameters used were:
Curtain Gas: 30; CAD: High; Ion Spray Voltage: -3500V; Temperature: 500°C; Gas 1: 40; Gas 2: 60;
Declustering Potential, Collision Energy, and Cell Exit Potential vary per transition. Multiple reaction monitoring transitions utilized for the eicosanoids can be found in Supplemental Table 1 .
Ceramide-1-phosphate/sphingolipid analysis: MEFs (2 × 10 6 ) or BMDMs were plated on 10-cm plates in the appropriate medium and grown under standard incubator conditions overnight. The next day cells were subjected to the relevant treatment. After treatment, the plates were placed on ice, cells washed twice with ice-cold PBS, and cells harvested by scraping in 200 μl of PBS followed by sonication to obtain a homogenous mixture. Lipids were extracted from the remaining cells using a modified Bligh and Dyer method and analyzed as described by Wijesinghe et al. (21) . Briefly, to 200 μl of the cells in PBS, 1.5 ml of 2:1 methanol:chloroform was added. The samples were spiked with 500 pmol of d 18:1/12:0 C1P, sphingomyelin, ceramide, and monohexosylceramide as the internal standard (Avanti). The mixture was sonicated to disperse the cell clumps and incubated for six hours at 48 °C. The samples were then sonicated, followed by centrifugation to separate particulates. The extracts were then dried down and reconstituted in methanol. The reconstituted samples were then sonicated, incubated at 48°C for 15 minutes, vortexed, and then incubated for an additional 15 sphingomyelin, and monohexosylceramide under positive ionization. Multiple reaction monitoring transitions utilized for C1P, ceramide, sphingomyelin, and monohexosylceramide can be found in Supplemental Table 2 . ) were plated in 24 well plates in the appropriate medium and were grown under standard incubation conditions overnight. The next day, the medium was replaced and 0.25 µCi [ 3 H]-AA was added for an incubation period of 4 hours. Then the medium was collected, and the cells were harvested. The radioactivity was determined in both the supernatants and the cells using a scintillation counter as previously described by our laboratory (22,33-34). FBS for two hours. After two hours, the 0% serum media was removed, and the cells were treated with A23187 (5 µM in 0% FBS medium), DMSO (1:5000 in 0% FBS medium), or medium for five minutes. After five minutes, the medium was collected and centrifuged, and the cells were harvested. The radioactivity was determined in both the supernatants and the cells using a scintillation counter as previously described by our laboratory (22,33-35).
Steady-state labeling (A23187)
:
Statistical Analysis:
Data from experiments involving the comparison of only two groups are plotted as mean ± standard deviation. Significance testing was performed using a two-tailed, independent sample t-test to compare means. For all other studies involving multiple experimental groups, measured values are presented as mean ± standard error. One-way ANOVA and Tukey's post-hoc analysis were used for pair-wise comparison of experimental groups. Analysis was performed on statistical software (IBM SPSS statistics 19.0) with p < 0.05 being considered significant.
Ethical considerations:
Breeding pairs of the CERK -/-mice (BALB/c background) and wild-type BALB/c counterparts were obtained from Dr. Frederick Bornancin of Novartis International (23) and were bred kept in the animal care facility at VCU. The mouse studies were undertaken under the supervision and approval of the VCU IACUC (Protocol# AM10089) following standards set by the Federal and State government. The animal assurance number for VCU is A2381-01.
Results

Genetic ablation of ceramide kinase reduces basal ceramide-1-phosphate levels
Previously, we confirmed that knockdown of ceramide kinase by siRNA technology reduced C1P levels in A549 cells (15) demonstrating that CERK was an anabolic enzyme for C1P formation in these cells.
Additionally, Graf and coworkers demonstrated the production of To ensure that the C1P downregulation observed in the CERK -/-MEFs was not due to a reduction in ceramide, ceramide levels were also analyzed ( Figure 1 . These data demonstrate that CERK is a major regulator of C1P
biosynthesis, but the specific chain lengths of C1P subspecies produced by CERK varies in response to immortalization and between cell types.
Genetic ablation of ceramide kinase affects basal eicosanoid synthesis
Previously, we have shown that the association of CERK-derived C1P with cPLA 2 α is required for the synthesis of eicosanoids in response to inflammatory agonists (15) . Therefore, we chose to characterize CERK ablation models for eicosanoid production. First, we examined the basal eicosanoid production produced by immortalized MEFs from CERK +/+ mice using HPLC-ESI-MS/MS. Of the 15 eicosanoids examined, six were detected in quantifiable amounts (Table 1) . Specifically, arachidonic acid, PGE 2 , PGF 2 α, 6-keto PGF 1 α, 5-HETE and 11-HETE were basally produced in appreciable amounts by CERK +/+ MEFs.
Importantly, the production these eicosanoids were significantly reduced in CERK -/-cells with the exception of PGF 2 α, which was surprisingly increased in the CERK -/-MEFs ( Figure 3 and Table 1 and PGD 2 were downregulated approximately 25% (Supplemental Figure 1 and After observing the differences in the MEFs, we next determined if these effects were cell-type specific.
Therefore, we again utilized primary BMDMs obtained from both CERK +/+ and CERK -/-mice (Supplemental Figure 2 and reductions. These results suggest that the overall deficiency in eicosanoid production induced by the loss of CERK translates to multiple cell types.
Next, the effects of serum in the tissue culture media were examined as previous reported studies with CERK -/-cells utilized 10% serum in the culture media (5) . We surmised that the C1P present in the FBS used to supplement tissue culture media could affect both C1P and eicosanoid levels. In this regard, the quantities of the various chain lengths of C1P were again examined in the wild type and the CERK -/-MEFs cultured in 10% serum (Figure 4 ). Similarly to the C1P levels found when the MEFs were incubated with media containing no serum, the levels of C 18:1/22:0 C1P, C 18:1/24:1 C1P, and C 18:1/24:0 C1P were downregulated in the CERK -/-MEFs.
However, with the inclusion of 10% FBS in the media, an approximately 2-fold upregulation of C 18:1/14:0 C1P
was observed in the CERK -/-MEFs when compared with the CERK +/+ MEFs. When the levels of C1P are compared between the no serum treatment and the 10% serum treatment, C 18:1/16:0 C1P appears to have higher levels in 10% serum. In contrast, the addition of serum in the media reduced the C 18:1/24:0 levels found in both cell types. Overall, these data illustrating the differences in C1P levels based upon the amount of serum in the media suggest that MEFs have the ability to partially adapt to C1P deficiency.
To determine if the increase of C1P induced by serum correlated with an effect on eicosanoid biosynthesis, basal eicosanoid production was again examined. Of the 15 eicosanoids examined, 11 were produced in quantifiable amounts when immortalized MEFs were treated with 10% serum in contrast to the six detected when treated with 0% serum (Supplemental Figure 3 and Table 4 ). Specifically, arachidonic acid, PGE 2 , PGD 2 , PGF 2 α, 6-keto PGF 1 α, PGJ 2 , 5-HETE, 8-HETE, 11-HETE, 12-HETE, and 15-HETE were basally produced in appreciable amounts by CERK +/+ MEFs. These 11 eicosanoids were also produced in quantifiable amounts in the CERK -/-MEFs. The levels of these eicosanoids were again reduced in the CERK -/-cells with the exception of PGD 2 and PGF 2 α being produced at higher levels in the CERK -/-MEFs. The overall levels of eicosanoids were significantly upregulated in both cell types with respect to the levels produced for basal eicosanoids without FBS supplementation. Interestingly, the levels of arachidonic acid, PGF 2 α, and 5-HETE were greatly increased when comparing the percent control values for CERK -/-MEFs between the 0% serum treatment and the 10% serum treatment (Table 4) , while PGE 2 levels were decreased when comparing the percent control values (Table 4) . These results further illustrate the inherent difference of tissue culture conditions on basal eicosanoid production in the CERK -/-MEFs when compared to wild type counterparts.
After observing the differences in basal eicosanoid synthesis between the CERK +/+ and CERK -/-MEFs, we questioned whether the differences in eicosanoid synthesis were due to a dysfunction in the uptake of 
Genetic ablation of CERK leads to dysfunction of arachidonic acid release and eicosanoid synthesis in response to calcium ionophore
Previously, our laboratory demonstrated that the interaction between C1P and cPLA 2 α is required for the activation/translocation of cPLA 2 α in response to inflammatory agonists (e.g. the calcium ionophore, A23187 MEFs demonstrated a startling reduction in these same eicosanoids with the fold-stimulation of the A23187 response significantly inhibited ( Figure 5 A-C). No significant differences were observed between the no treatment and the DMSO control samples. These data demonstrate that the production of eicosanoids in response to calcium ionophore is dysfunctional in CERK -/-cells.
This effect of genetic ablation of CERK on eicosanoid synthesis was confirmed at the level of arachidonic acid release using steady-state labeling with [ 
The CERK -/-mouse has adapted in regards to airway hyper-responsiveness
As we now hypothesized that the CERK -/-mouse has partially adapted to loss of CERK by producing C1P via a separate anabolic pathway, the genetic loss of CERK was compared to acute induced-loss of CERK via siRNA in an inflammatory phenotype. Airway hyper-responsiveness was evaluated in relation to the loss of CERK as the cPLA 2 α knockout mouse demonstrated reduced eicosanoid production upon OVAchallenge/rechallenge (37). OVA was i.p. injected on Day 1 and Day 5, then these mice were rechallenged by aerosolized OVA on Days 14-20 (1 hour/day). siRNA was given to mice via i.p. injection on Day 13 ( Figure   7A ), and mice were sacrificed on Day 21 (10 hours post challenge) with the lungs and BAL fluid collected. In our study, siRNA was utilized to knock down ceramide kinase levels in the lungs of wild type mice, and these mice were evaluated for airway hyper-responsiveness. The CERK siRNA introduced to the mice successfully infiltrated the lung and downregulated the production of CERK ( Figure 7B ). BAL fluid was evaluated for eicosanoid production via ELISA, and three eicosanoids, PGE 2 , PGD 2 , and TXB 2 were upregulated upon challenge with ovalbumin ( Figure 7C -E). In addition, the production of PGE 2 and PGD 2 was significantly decreased with the acute downregulation of CERK when mice were challenged with ovalbumin ( Figure 7C and D), while the downregulation of CERK had no effect on TXB 2 production ( Figure 7E ). Cell infiltration in the BAL fluid was also characterized, and no significant differences were observed between control siRNA and CERK siRNA treated mice demonstrating that the observed differences were not due to loss of eosinophil infiltration by guest, on November 9, 2017 www.jlr.org
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Discussion
In this study, we have demonstrated that CERK-derived C1P is instrumental in the production of eicosanoids, corroborating our previous studies illustrating that siRNA downregulation of CERK blocks the release arachidonic acid by inhibiting the production of CERK-derived C1P (15, 22) . As we have shown here, cells derived from the CERK -/-mice and tested under reduced serum conditions are dysfunctional in eicosanoid synthesis, both basally and in response to calcium ionophore. This further illustrates the effects of CERKderived C1P on eicosanoid production, and therefore implicates these mediators as players in the inflammatory response. Of note, these findings are partially in opposition to the reports by Bornancin and co-workers (23-24,49). Specifically, this group explored how cPLA 2 α-dependent pathways were affected by the genetic ablation of CERK and this laboratory observed similar responses of cells derived from both wild type and knockout animals to PMA/Ionomycin treatment as well as the susceptibility of the whole animals to arthritis induction by both Ag and KRN serum. As cPLA 2 α function is imperative in these responses, Bornancin and coworkers concluded that cPLA 2 α-dependent pathways were functional. However, after this study was released, our laboratory reported the C1P binding site on the cPLA 2 α protein and showed that both reduction in C1P and mutation of this binding site reduced the activity of cPLA 2 α (19). These contradictory results gave rise to the current study using cells from the same genetic model, and this study demonstrates several differences in approaches that may explain the contrasting findings. For example, most of our cellular MEF results demonstrating dysregulation in eicosanoids utilized either no serum or low serum environments in comparison to the Bornancin study. Indeed, as we increase serum levels, the effect on both total C1P levels and the basal generation of eicosanoids becomes partially "rescued". Furthermore, a novel chain length of C1P
is increased in the CERK -/-cells, which may account for the minor phenotype on eicosanoids observed in a high serum environment. Regardless, MEFs from the CERK -/-mouse presented with reduced levels of C1P, and the role of C1P in regulating cPLA 2  responses may be cell type specific. For example, the C1P levels in BMDMs are several-fold higher than the fibroblasts regardless of serum concentration utilized for MEFs, and the effect on basal eicosanoids is also more dramatic in BMDMs from CERK -/-cells. Hence, differential effects on eicosanoids in regards to C1P may vary greatly from cell-type to cell-type. Indeed, the reports by Bornancin and co-workers also used different cell types, specifically primary kidney fibroblasts and peritoneal macrophages (23,36). Unfortunately, we were unable to obtain peritoneal macrophages using thioglycolate in the CERK -/-animals in contrast to CERK +/+ . Hence, we could not undertake the same studies, and relied on BMDMs for comparison. We attribute the lack of macrophage infiltration in response to thioglycolate to the reported neutropenia as neutrophils are strongly linked to macrophage infiltration (23).
Another difference between the studies is the use of PMA/ionomycin versus our use of only calcium ionophore in regards to AA release. PMA drives activation of protein kinase C, which has been strongly linked to cPLA 2  activation (50-53). This activation may or may not be dependent on C1P, and unpublished findings from our laboratory show that a DAG lipase inhibitor is a dramatic stimulator of eicosanoid synthesis without by guest, on November 9, 2017 www.jlr.org Downloaded from the requirement of C1P. Regardless, this study and the Graf studies are not dramatically divergent with technical differences explaining many of the contrasting findings for the cell studies.
As culture conditions, technical details, and differences in cell types may explain the incongruent findings between our laboratory and the reports by Bornancin and co-workers, the only remaining conundrums in regards to CERK and eicosanoid synthesis is the report by Bornancin and co-workers as to the relative lack of phenotypes in the CERK -/-animals for eicosanoid biosynthesis as well as the more recent report using a specific CERK inhibitor (NVP-231) in vitro (49). In regards to the CERK -/-mouse, this genetic ablation model does not demonstrate the phenotypes observed in the cPLA 2 α knockout mouse (e.g. resistance to arthritis induction by both Ag and KRN serum and OVA-induced airway hyper-responsiveness (AHR)) with the exception of one report by Bornanicin and co-workers showing a reduction in the levels of basal PGE 2 in the BAL fluid of the CERK -/-mice (23-24). As a decade of research from our laboratory and others has shown cPLA 2  to possess a specific C1P-interaction site, we hypothesized that the CERK -/-mice were able to demonstrate intact cPLA 2 α-dependent pathways due to an adaptation of the whole mouse to the loss of CERKderived C1P (15) (16) (17) (18) (19) (20) 22, (33) (34) (35) . For example, no differences in total C1P levels were observed in the serum of the mice, which correlates well with C1P data obtained from primary hepatocytes (54). Thus, not all cells produce C1P via CERK, and as our cell studies showed, other cells can at least partially adapt to loss of CERK via upregulating novel chain lengths of C1P (54). This effect was also observed by genetic ablation of CERK in HeLa cells via zinc-finger nuclease technology (54). Indeed, the levels of C1P were increased upon ablation of CERK in these cells via an unknown anabolic pathway (54). This type of adaptation could explain the lack of phenotypes observed in the CERK knockout mouse. The hypothesis of the adaption of the CERK -/-mice to loss of C1P is supported by our airway hyper-responsiveness (AHR) studies presented in this manuscript. An effect on eicosanoid production induced by AHR was observed when CERK was downregulated via siRNA, but the same effect was not seen in the evaluation of the CERK -/-mice. These types of differences have also been observed in some phenotypes for the genetic ablation model of cPLA 2 α in comparison to the acute inhibition/downregulation of the enzyme by utilization of cPLA 2 α inhibitors and siRNA (55-57). Overall, our studies highlight the difficulty of examining complex and important pathways in mammalian physiology due to compensatory pathways, which highlight the difficulty in understanding the role of cPLA 2 α, in general, as well as via the activation of lipid co-factors. Thus, for examining the role of a protein:lipid interaction, it may be necessary to identify the binding site and ablate this site genetically in a mouse to determine function. This may be one alternative route to determining the role of a particular bioactive lipid in a particular biology to overcome compensatory mechanisms when targeting the biosynthetic pathways.
As stated previously, there is still the question of the CERK inhibitor (NVP-231) developed by Novartis (49).
Bornancin and co-workers reported that treatment of cells with this inhibitor had no effect on the stimulation of eicosanoid synthesis by various inflammatory agonists (49). Our laboratory has only sparingly utilized this inhibitor, but concur that the inhibitor dramatically reduces total C1P levels with 1hr of treatment in primary MEFs (Supplemental Figure 5) . Interestingly, the inhibitor potently and dramatically lowers the synthesis of all chain lengths of C1P, with the exception of C 18:1/14:0 C1P, in contrast to CERK siRNA (15, (21) (22) ) and CERK ablation (23,25). Thus, the CERK inhibitor may also block the currently unknown anabolic pathways of C1P biosynthesis as well as CERK. Therefore, this inhibitor may be an excellent "tool" to examine C1P biology as the entirety of the C1P anabolic system is possibly blocked. What additional targets the inhibitor may be affecting is unknown, but the lack of effect on the levels of ceramide suggests that the unknown pathways are not ceramide kinases. On the other hand, ceramide may be quickly metabolized to hexosylceramides in MEFs masking any increases in ceramide induced by CERK inhibition. As the levels of C1P in comparison to ceramide and phostphatidic acid (PA) are very low, a DAG kinase (DAGK) with low activity toward ceramide could account for some of the C1P formed in cells, and examination of DAG and PA levels in the presence of this inhibitor may be warranted. Furthermore, DAGK has high homology to CERK (58), and Bornancin and co-workers only examined DAGK for efficacy (49). Overall, future studies will also include the use of this CERK inhibitor and examining a number of cell types and inflammatory agonists under various culture conditions to determine whether C1P plays a role in AA release and eicosanoid synthesis. The broad use of this inhibitor coupled to findings using a mouse model with the C1P interaction site ablated from cPLA 2  may finally answer the question as to the role of C1P in regulating cPLA 2  activation. Furthermore, investigations as to whether this inhibitor will reduce the levels of C1P in cells from the CERK -/-mouse as well as the CERK -/-HeLa cells will confirm the inhibition of a separate anabolic pathway for C1P formation. Indeed, these cell models may prove useful in defining these unknown anabolic pathways for C1P as well as investigate their roles in biological mechanisms.
In conclusion, this study utilizing ex vivo cells supports previous results from our laboratory for the role of CERK in the activation of cPLA 2 α and regulation of eicosanoid synthesis. This study demonstrates that cells derived from the CERK -/-mice are dysfunctional in eicosanoid synthesis, both basally and through induction by calcium ionophore. C1P levels appear to be partially rescued via addition of serum to the culture medium, which mimics the possible adaptation of the CERK -/-mice. This adaptation of the CERK -/-mice was also demonstrated via the AHR study in comparison to acute downregulation. As inflammation plays a critical role in many diseases, understanding how these interactions modulate eicosanoid levels could lead to potential new drug targets for disease therapies. These new treatments could be vast improvements over current therapies which shunt eicosanoid production from one set of enzymes to another, creating additional health issues as a result of treatment.
22. Pettus, B.J., Bielawska, A., Spiegel, S., Roddy, P., Hannun, Y.A., Chalfant, C.E. 49. Graf, C., Klumpp, M., Habig, M., Rovina, P., Billich, A., Baumruker, T., Oberhauser, B., Bornancin, F. The next morning, the medium was replaced with 2% serum medium for two hours and were then switched to 0% serum media and incubated for four hours. Media was then collected and analyzed via HPLC-ESI MS/MS as described in the Materials and Methods section to evaluate the levels of (A) arachidonic acid, (B) PGE 2, (C) 
